Invasive pneumococcal disease in children younger than 5 years in Navarra, Spain (2000-2005). Impact of the conjugate vaccine;Enfermedad neumocócica invasiva en la población menor de 5 años de edad de Navarra (2000-2005): Impacto de la vacuna conjugada

Medicina Clinica

Volumn 129, Issue 2, 2007, Pages 41-45

  Barricarte, Aurelio ^a,b   Gil Setas, Alberto ^c   Torroba, Luis ^d   Castilla, Jesús ^a,b   Petit, Alba ^e   Polo, Isabel ^f   Arriazu, Maite ^a   Irisarri, Fátima ^a   Cenoz, Manuel García ^a  

^a INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c Ambulatorio General Solchaga   (Spain)

^d Universidad Pública de Navarra   (Spain)

^e HOSPITAL GARCÍA ORCOYEN   (Spain)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Epidemiological surveillance; Incidence; Pneumococcal meningitis; Streptococcus pneumoniae; Vaccination

Indexed keywords

7 VALENT PNEUMOCOCCAL CONJUGATE VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; BACTERIUM ISOLATION; BODY FLUID; DISEASE SURVEILLANCE; DRUG UTILIZATION; GROUPS BY AGE; HUMAN; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RATE; INVASIVE PNEUMOCOCCAL DISEASE; PRESCHOOL CHILD; SPAIN; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 34548556125     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13106935     Document Type: Article

References (30)

1. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumoccocal serotypes. Lancet Infect Dis. 2005;5:83-93.
2. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis. 2000;30:100-21.
3. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000;19:187-95.
4. O'Brien KL, Moulton LH, Reid R, Weatherholtz R, Oski J, Brown L, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet. 2003;362:355-61.
5. Black S, Shinefield H, Baxter R, Austrian R, Bracken L, Hansen J, et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J. 2004;23:485-9.
6. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-46.
7. Haddy RI, Perry K, Chacko CE, Helton WB, Bowling MG, Looney SW, et al. Comparison of incidence of invasive Streptococcus pneumoniae disease among children before and after introduction of conjugated pneumococcal vaccine. Pediatr Infect Dis J. 2005;24:320-3.
8. Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb Mortal Wkly Rep. 2005;54:893-7.
9. Poehling KA, Talbot TR, Griffin MR, Craig AS, Whitney CG, Zell E, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA. 2006;295:1668-74.
10. Jefferson T, Ferroni E, Curtale F, Rossi PG, Borgia P. Streptococcus pneumoniae in Western Europe: serotype distribution and incidence in children less than 2 years old. Lancet Infect Dis. 2006;6:405-10.
11. Comité Asesor de Vacunas de la Asociación Española de Pediatría. La enfermedad neumocócica y su prevención. Vacuna neumocócica conjugada heptavalente. An Esp Pediatr. 2002;56:79-90.
12. Calbo E, Díaz A, Cañadell E, Fábrega J, Uriz S, Xercavins M, et al. Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine. Clin Microbiol Infect. 2006;12:867-72.
13. Fenoll A, Jado I, Vicioso D, Pérez A, Casal J. Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: update (1990-1996). J Clin Microbiol. 1998;36:3447-54.
14. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344:403-9.
15. Veenhoven R, Bogaert D, Uiterwaal C, Brouwer C, Kiezebrink H, Bruin J, et al. Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study. Lancet. 2003;361:2189-95.
16. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294:2043-51.
17. Kaplan SL, Mason EO Jr, Wald ER, Schutze GE, Bradley JS, Tan TQ, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. 2004;113:443-9.
18. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006;354:1455-63.
19. Steenhoff AP, Shah AA, Ratner AJ, Patil SM, McGowan KL. Emergence of vaccine-related pneumococcal serotypes as a cause of bacteremia. Clin Infect Dis. 2006;42:907-14.
20. González BE, Hulten KG, Lamberth L, Kaplan SL, Mason EO Jr and the US Pediatric Multicenter Pneumococcal Surveillance Group. Streptococcus pneumoniae serogroups 15 and 33: an increasing cause of pneumococcal infections in children in the United States after the introduction of the pneumococcal 7-valent conjugate vaccine. Pediatr Infect Dis J. 2006;25:301-5.
21. Byington CL, Samore MH, Stoddard GJ, Barlow S, Daly J, Korgenski K, et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin Infect Dis. 2005;41:21-9.
22. Hsu K, Pelton S, Karumuri S, Heisey-Grove D, Klein J, and Massachusetts Department of Public Health Epidemiologists. Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine. Pediatr Infect Dis J. 2005;24:17-23.
23. Yu X, Gray B, Chang S, Ward JI, Edwards KM, Nahm MH. Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants. J Infect Dis. 1999;180:1569-76.
24. Vakevainen M, Eklund C, Eskola J, Käyhty H. Cross-reactivity of antibodies to type 6B and 6A polysaccharides of Streptococcus pneumoniae, evoked by pneumococcal conjugate vaccines, in infants. J Infect Dis. 2001;184:789-93.
25. Pai R, Moore MR, Pilishvili T, Gertz RE, Withney CG, Beall B and the Active Bacterial Core Surveillance Team. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis. 2005;192:1988-95.
26. Käythy H, Ahman H, Eriksson K, Sörberg M, Nilsson L. Immunogenicity and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatr Infect Dis J. 2005;24:108-14.
27. Ministère de la Santé, et des Solidarités. Avis du Conseil Supérieur d'Hygiène Publique de France. Relatif à la vaccination par le vaccine antipneumococcique conjugué chez les enfants de moins de deux ans, et les enfants de deux à cinq ans. Séance du 19 mai 2006 [consultado 20/11/2006]. Disponible en: http://nosobase.chu-lyon.fr/recommandations/RCSHPF/a_mt_190506_pneumo_enf.pdf
28. Bergsaker MAR, Feiring B. Introduction of pneumococcal conjugate vaccine into the Norwegian childhood vaccination programme. Euro Surveill. 2006;11:E060202.5 [consultado 04/08/2006]. Disponible en: http://www. eurosurveillance.org/ew/2006/060202.asp
29. Cameron C, Pebody R. Introduction of pneumococcal conjugate vaccine to the UK childhood immunisation programme, and changes to the meningitis C and Hib schedules. Euro Surveill. 2006;11:E060302.4 [consultado 04/08/2006]. Disponible en: http://www.eurosurveillance.org/ew/2006/060302.asp
30. Van Oosten M, De Greeff SC, Spanjaard L, Schouls LM. Introduction of pneumococcal conjugate vaccine into the Dutch national immunisation programme. Euro Surveill. 2006;11:E060608.2 [consultado 04/08/2006]. Disponible en: http://www.eurosurveillance.org/ew/2006/060608.asp